glp 1 and ibd Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, therapeutic potential Gut Hormones and Inflammatory Bowel
Description
A review published in 2025 found that significant weight regain occurred after 8 weeks of stopping weight loss medication
When discussing GLP-1 eligibility with your provider, sharing your genetic predispositions in peptide pathways alongside your clinical history can help shape a personalized treatment plan
The highest risk appears to be in patients with type 2 diabetes who have established diabetic retinopathy at the time of treatment initiation, particularly when aggressive glycemic targets are pursued rapidly without appropriate ophthalmologic monitoring
Eliud Sifonte, a diabetes and metabolism endocrinologist affiliated with NYU Langone Health, told Flow Space
